PharmaCyte Biotech Inc (PMCB)

[joe_techi]

Von Hoff History with developing FDA approved drugs for pancreatic cancer. Here is an example of Von Hoff combining drugs to increase overall effectiveness, much like with Nuvilex.

This August 2010 article says:
“Von Hoff and his team also are conducting clinical trials that combine gemcitabine with another anti-cancer drug called nab-paclitaxel. Earlier this year, they reported a one-year survivorship of 52 percent, double the rate for patients who took only gemcitabine. A larger clinical study is under way.

Von Hoff's goal is to find a cure for pancreatic cancer before he retires.”
http://www.azcentral.com/arizonarepublic/news/articles/2010/08/08/20100808valley-cancer-doctor.html

This September 2013 site says:
“The FDA has approved nab-paclitaxel (Abraxane) plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.
The approval was based on results from the MPACT trial, which showed that weekly nab-paclitaxel, a nanoparticle albumin-bound (nab) formulation of paclitaxel, combined with gemcitabine significantly improved both overall survival (OS) and progression-free survival (PFS), when compared with gemcitabine alone."

http://www.onclive.com/web-exclusives/FDA-Approves-Nab-Paclitaxel-for-Advanced-Pancreatic-Cancer

Von Hoff certainly has the ability to deliver on his endeavors. In 2010 Von Hoff was 63 making him about 67 now….right around retirement age. IMO, Nuvilex’s Cell-in-a-Box® technology combined with ifosfamide…..and FDA's Accelerated Approval Program fits the bill for Von Hoff’s life goals. I hope so.